U.S. markets open in 1 hour 19 minutes
  • S&P Futures

    3,718.25
    +48.25 (+1.31%)
     
  • Dow Futures

    29,650.00
    +307.00 (+1.05%)
     
  • Nasdaq Futures

    11,495.25
    +179.00 (+1.58%)
     
  • Russell 2000 Futures

    1,688.00
    +25.50 (+1.53%)
     
  • Crude Oil

    77.82
    +1.11 (+1.45%)
     
  • Gold

    1,644.40
    +11.00 (+0.67%)
     
  • Silver

    18.69
    +0.21 (+1.14%)
     
  • EUR/USD

    0.9641
    +0.0030 (+0.31%)
     
  • 10-Yr Bond

    3.8780
    0.0000 (0.00%)
     
  • Vix

    30.81
    +0.89 (+2.97%)
     
  • GBP/USD

    1.0803
    +0.0120 (+1.12%)
     
  • USD/JPY

    144.4580
    -0.2220 (-0.15%)
     
  • BTC-USD

    20,248.55
    +1,390.07 (+7.37%)
     
  • CMC Crypto 200

    462.44
    +29.34 (+6.77%)
     
  • FTSE 100

    7,041.97
    +21.02 (+0.30%)
     
  • Nikkei 225

    26,571.87
    +140.32 (+0.53%)
     

Erythropoietin Stimulating Agents Market to register USD 4.74 Bn growth - Technavio

·13 min read

NEW YORK, Sept. 14, 2022 /PRNewswire/ -- Technavio has been monitoring the Erythropoietin Stimulating Agents Market, operating under the health care industry. The report estimates the market to register an incremental growth of USD 4.74 billion, at a CAGR of 8.9% during the forecast period. The report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Request the Latest Free sample report

Technavio has announced its latest market research report titled Erythropoietin Stimulating Agents Market by Type and Geography - Forecast and Analysis 2022-2026
Technavio has announced its latest market research report titled Erythropoietin Stimulating Agents Market by Type and Geography - Forecast and Analysis 2022-2026

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Competitors have to focus on differentiating their product offerings with unique value propositions to strengthen their foothold in the market.

Market vendors also have to leverage the existing growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments. 3SBio Inc., Akebia Therapeutics Inc., Amgen Inc., Biocon Ltd., Biosidus SA, Dr. Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., LG Chem Ltd., Pieris Pharmaceuticals Inc., Reliance Industries Ltd., Thermo Fisher Scientific Inc., and Zydus Lifesciences Ltd. are among some of the major market participants.

The presence of a large pool of CKD patients has been instrumental in driving the growth of the market. However, stringent government regulations might hamper the market growth. Buy Sample Report.

Erythropoietin Stimulating Agents Market Segmentation

Based on geographic segmentation, 42% of the market's originated from North America during the forecast period. In addition, the Epoetin Alfa category led the growth under the type segment. This report provides an accurate prediction of the contribution of all the segments to the growth of the superfood powders market size.

  • Type

  • Geography

Erythropoietin Stimulating Agents Market Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The erythropoietin stimulating agents market report covers the following areas:

  • Erythropoietin Stimulating Agents Market Size

  • Erythropoietin Stimulating Agents Market Trends

  • Erythropoietin Stimulating Agents Market Industry Analysis

This study identifies the growing number of CKD dialysis centers in developing economies as one of the prime reasons driving the Erythropoietin Stimulating Agents Market growth during the next few years. Download Free Sample Report.

Erythropoietin Stimulating Agents Market Key Highlights

  • CAGR of the market during the forecast period

  • Detailed information on factors that will assist erythropoietin stimulating agents market growth during the next five years

  • Estimation of the erythropoietin stimulating agents market size and its contribution to the parent market

  • Predictions on upcoming trends and changes in consumer behavior

  • The growth of the erythropoietin stimulating agents market

  • Analysis of the market's competitive landscape and detailed information on vendors

  • Comprehensive details of factors that will challenge the growth of the erythropoietin stimulating agents market, vendors

Related Reports

Stem Cell Umbilical Cord Blood (UCB) Market by End-user and Geography - Forecast and Analysis 2022-2026: The stem cell umbilical cord blood (UCB) market share is expected to increase by $ 1.47 bn from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 16.87%.

Pregabalin Market by Application and Geography - Forecast and Analysis 2022-2026: The pregabalin market share is expected to increase by USD 153.03 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 3.74%.

Erythropoietin Stimulating Agents Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 8.9%

Market growth 2022-2026

$ 4.74 billion

Market structure

Fragmented

YoY growth (%)

8.3

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 42%

Key consumer countries

US, Canada, Germany, UK, and China

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

3SBio Inc., Akebia Therapeutics Inc., Amgen Inc., Biocon Ltd., Biosidus SA, Dr. Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Johnson and Johnson, LG Chem Ltd., Nanogen Pharmaceutical Biotechnology, Novartis AG, Pfizer Inc., Pieris Pharmaceuticals Inc., Reliance Industries Ltd., Thermo Fisher Scientific Inc., and Zydus Lifesciences Ltd.

Market Dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Browse for Technavio "Health Care" Research Reports

Table of Contents:

1 Executive Summary

  • 1.1 Market overview

2 Market Landscape

  • 2.1 Market ecosystem

3 Market Sizing

  • 3.1 Market definition

  • 3.2 Market segment analysis

  • 3.3 Market size 2021

  • 3.4 Market outlook: Forecast for 2021-2026

4 Five Forces Analysis

  • 4.1 Five forces summary

  • 4.2 Bargaining power of buyers

  • 4.3 Bargaining power of suppliers

  • 4.4 Threat of new entrants

  • 4.5 Threat of substitutes

  • 4.6 Threat of rivalry

  • 4.7 Market condition

5 Market Segmentation by Type

  • 5.1 Market segments

  • 5.2 Comparison by Type

  • 5.3 Epoetin alfa - Market size and forecast 2021-2026

  • 5.4 Epoetin beta - Market size and forecast 2021-2026

  • 5.5 Darbepoetin alfa - Market size and forecast 2021-2026

  • 5.6 Others - Market size and forecast 2021-2026

  • 5.7 Market opportunity by Type

6 Customer Landscape

  • 6.1 Customer landscape overview

7 Geographic Landscape

  • 7.1 Geographic segmentation

  • 7.2 Geographic comparison

  • 7.3 North America - Market size and forecast 2021-2026

  • 7.4 Europe - Market size and forecast 2021-2026

  • 7.5 Asia - Market size and forecast 2021-2026

  • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026

  • 7.7 US - Market size and forecast 2021-2026

  • 7.8 Germany - Market size and forecast 2021-2026

  • 7.9 UK - Market size and forecast 2021-2026

  • 7.10 Canada - Market size and forecast 2021-2026

  • 7.11 China - Market size and forecast 2021-2026

  • 7.12 Market opportunity by geography

8 Drivers, Challenges, and Trends

  • 8.1 Market drivers

  • 8.2 Market challenges

  • 8.3 Impact of drivers and challenges

  • 8.4 Market trends

9 Vendor Landscape

  • 9.1 Overview

  • 9.2 Vendor landscape

  • 9.3 Landscape disruption

  • 9.4 Industry risks

10 Vendor Analysis

  • 10.1 Vendors covered

  • 10.2 Market positioning of vendors

  • 10.3 Akebia Therapeutics Inc.

  • 10.4 Amgen Inc.

  • 10.5 Biocon Ltd.

  • 10.6 Biosidus SA

  • 10.7 F. Hoffmann La Roche Ltd.

  • 10.8 Johnson and Johnson

  • 10.9 Nanogen Pharmaceutical Biotechnology

  • 10.10 Novartis AG

  • 10.11 Pfizer Inc.

  • 10.12 Thermo Fisher Scientific Inc.

11 Appendix

  • 11.1 Scope of the report

  • 11.2 Inclusions and exclusions checklist

  • 11.3 Currency conversion rates for US$

  • 11.4 Research methodology

  • 11.5 List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Technavio (PRNewsfoto/Technavio)
Technavio (PRNewsfoto/Technavio)
Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/erythropoietin-stimulating-agents-market-to-register-usd-4-74-bn-growth---technavio-301623358.html

SOURCE Technavio